|
|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | When I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting. | |
|
|
|
By S. Jain, Consultant, Manufacturing Sciences and CMC | Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance. | |
|
|
|
In this Advancing RNA Live segment, several speakers raise concerns about the industry's ability to accurately measure impurities, particularly dsRNA, arguing that current analytics are insufficient, especially for high-dose therapeutics. |
|
|
|
|
| 5 Outdated Practices Holding Back Modern Bioanalysis | Article | By Ander Tallett, Dash Bio | Bioanalysis must replace outdated manual processes and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies. |
|
|
|
|
| Manufacturing Strategies For mRNA Vaccines And Therapeutics | White Paper | By L. Vergauwen, Dr. N. El Hajjami, M. Manuel Brantner, et al., MilliporeSigma | mRNA has emerged as a promising modality offering a great deal of versatility for a wide range of therapeutics and vaccines with its use of non-viral delivery systems. |
|
|
|
|
| In-Process Control Of pDNA Production | Application Note | Sartorius | Real-time in-process control is vital for high-quality plasmid DNA production. This method monitors pDNA conformations and impurity removal, enabling efficient, cost-effective gene therapy manufacturing. |
|
|
|
|
|
|
|
.png){kind=logo}
